Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06679816
PHASE4

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Sponsor: Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the need for hydrocortisone replacement therapy during the perioperative period for large pituitary neuroendocrine tumors. The main questions it aims to answer are: • Does hydrocortisone replacement therapy reduce the incidence of adrenal insufficiency in participants? Researchers will compare hydrocortisone to a placebo (a look-alike substance that contains no drug) to see if hydrocortisone works to reduce the incidence of adrenal insufficiency. Participants will: * Take or intravenous infusion drug hydrocortisone or a placebo every day for 2 weeks * Visit the clinic three months after surgery for checkups and tests * Keep a diary of their symptoms

Official title: Study on the Efficacy of Hydrocortisone in Perioperative Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors:a Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled Study

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

882

Start Date

2024-12-04

Completion Date

2026-06-30

Last Updated

2025-01-14

Healthy Volunteers

No

Interventions

DRUG

Hormone replacement therapy

Perioperative Hydrocortisone Reduction Therapy

DRUG

Placebo

Perioperative placebo Reduction Therapy

Locations (1)

Beijing, Beijing Tiantan Hospital,Capital Medical University

Beijing, Beijing Municipality, China